Pipeline

Pipeline

mobile pipline

Aveta Biomics has developed multiple HOT assets with worldwide rights. We expect these assets to treat other diseases with common underlying disease biology. All drugs represent rational combinations of Orthologous Molecular Structures.

APG-157
Oral Squamous Cell Carcinoma
Phase 2
AMAX-126
Glioblastoma
Phase 1
COBRA
Drug Resistant UTI
Pre-clinical

APG-157

The worldwide incidence of OSCC is over 500,000 with a five year mortality rate of about 50% which has remained unchanged for decades. Highly molecularly heterogeneous tumor poses serious challenges for targeted approaches. The recurrence rates exceed 30%. APG-157, through a multi-targeted mechanism, kills active tumor through selective apoptosis and simultaneously stimulating the immune system. It further aims to prevent recurrence through the arrest of cancer stem cells. It is the first drug of its kind that is administered orally and thus has topical application as well as systemic absorption through the oral cavity.

AMAX-126

Glioblastoma is one of the brain cancers with a median survival of 12 to 14 months and represents a huge unmet need. Annual US incidence is over 13,000 patients. Molecular characteristics of this cancer present unique challenges. AMAX-126 works through a completely novel, multi-targeted mechanism. It is administered orally. 

COBRA

Antibiotics resistance is increasing worldwide which makes the treatment of urinary tract infection (UTI) difficult leading to chronic morbidity. In the US, 50% to 60% has a lifetime incidence of UTI. COBRA represents a new class of drugs. When co-administered with first-line antibiotics, they are aimed at preventing the resistance to the antibiotics in the first place and restoring the sensitivity of resistant pathogens to the antibiotics.

Scroll to Top